These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 30513619)

  • 21. Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.
    Al-Amri SS; Abbas AT; Siddiq LA; Alghamdi A; Sanki MA; Al-Muhanna MK; Alhabbab RY; Azhar EI; Li X; Hashem AM
    Sci Rep; 2017 Mar; 7():44875. PubMed ID: 28332568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibodies and vaccines against Middle East respiratory syndrome coronavirus.
    Xu J; Jia W; Wang P; Zhang S; Shi X; Wang X; Zhang L
    Emerg Microbes Infect; 2019; 8(1):841-856. PubMed ID: 31169078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospects for a MERS-CoV spike vaccine.
    Zhou Y; Jiang S; Du L
    Expert Rev Vaccines; 2018 Aug; 17(8):677-686. PubMed ID: 30058403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection.
    Pascal KE; Coleman CM; Mujica AO; Kamat V; Badithe A; Fairhurst J; Hunt C; Strein J; Berrebi A; Sisk JM; Matthews KL; Babb R; Chen G; Lai KM; Huang TT; Olson W; Yancopoulos GD; Stahl N; Frieman MB; Kyratsous CA
    Proc Natl Acad Sci U S A; 2015 Jul; 112(28):8738-43. PubMed ID: 26124093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development.
    Mubarak A; Alturaiki W; Hemida MG
    J Immunol Res; 2019; 2019():6491738. PubMed ID: 31089478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An In Silico Approach Applied to Emerging Infectious Diseases.
    Shi J; Zhang J; Li S; Sun J; Teng Y; Wu M; Li J; Li Y; Hu N; Wang H; Hu Y
    PLoS One; 2015; 10(12):e0144475. PubMed ID: 26641892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.
    Coleman CM; Venkataraman T; Liu YV; Glenn GM; Smith GE; Flyer DC; Frieman MB
    Vaccine; 2017 Mar; 35(12):1586-1589. PubMed ID: 28237499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.
    Wang Y; Tai W; Yang J; Zhao G; Sun S; Tseng CK; Jiang S; Zhou Y; Du L; Gao J
    Hum Vaccin Immunother; 2017 Jul; 13(7):1615-1624. PubMed ID: 28277821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein.
    Volz A; Kupke A; Song F; Jany S; Fux R; Shams-Eldin H; Schmidt J; Becker C; Eickmann M; Becker S; Sutter G
    J Virol; 2015 Aug; 89(16):8651-6. PubMed ID: 26018172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD.
    Wang C; Hua C; Xia S; Li W; Lu L; Jiang S
    Viruses; 2019 Jan; 11(1):. PubMed ID: 30621343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein.
    Rodon J; Okba NMA; Te N; van Dieren B; Bosch BJ; Bensaid A; Segalés J; Haagmans BL; Vergara-Alert J
    Emerg Microbes Infect; 2019; 8(1):1593-1603. PubMed ID: 31711379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice.
    Kato H; Takayama-Ito M; Iizuka-Shiota I; Fukushi S; Posadas-Herrera G; Horiya M; Satoh M; Yoshikawa T; Yamada S; Harada S; Fujii H; Shibamura M; Inagaki T; Morimoto K; Saijo M; Lim CK
    PLoS One; 2019; 14(10):e0223684. PubMed ID: 31589656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus.
    Choi JH; Woo HM; Lee TY; Lee SY; Shim SM; Park WJ; Yang JS; Kim JA; Yun MR; Kim DW; Kim SS; Zhang Y; Shi W; Wang L; Graham BS; Mascola JR; Wang N; McLellan JS; Lee JY; Lee H
    PLoS One; 2020; 15(5):e0232757. PubMed ID: 32384116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.
    Zhang N; Channappanavar R; Ma C; Wang L; Tang J; Garron T; Tao X; Tasneem S; Lu L; Tseng CT; Zhou Y; Perlman S; Jiang S; Du L
    Cell Mol Immunol; 2016 Mar; 13(2):180-90. PubMed ID: 25640653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset.
    Chen Z; Bao L; Chen C; Zou T; Xue Y; Li F; Lv Q; Gu S; Gao X; Cui S; Wang J; Qin C; Jin Q
    J Infect Dis; 2017 Jun; 215(12):1807-1815. PubMed ID: 28472421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model.
    Hashem AM; Algaissi A; Agrawal AS; Al-Amri SS; Alhabbab RY; Sohrab SS; S Almasoud A; Alharbi NK; Peng BH; Russell M; Li X; Tseng CK
    J Infect Dis; 2019 Oct; 220(10):1558-1567. PubMed ID: 30911758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein.
    Jiang L; Wang N; Zuo T; Shi X; Poon KM; Wu Y; Gao F; Li D; Wang R; Guo J; Fu L; Yuen KY; Zheng BJ; Wang X; Zhang L
    Sci Transl Med; 2014 Apr; 6(234):234ra59. PubMed ID: 24778414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human neutralizing antibodies against MERS coronavirus: implications for future immunotherapy.
    Tang XC; Marasco WA
    Immunotherapy; 2015; 7(6):591-4. PubMed ID: 26098703
    [No Abstract]   [Full Text] [Related]  

  • 39. MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques.
    Wang C; Zheng X; Gai W; Zhao Y; Wang H; Wang H; Feng N; Chi H; Qiu B; Li N; Wang T; Gao Y; Yang S; Xia X
    Oncotarget; 2017 Feb; 8(8):12686-12694. PubMed ID: 27050368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of MERS-CoV antigen on formalin-fixed paraffin-embedded nasal tissue of alpacas by immunohistochemistry using human monoclonal antibodies directed against different epitopes of the spike protein.
    Haverkamp AK; Bosch BJ; Spitzbarth I; Lehmbecker A; Te N; Bensaid A; Segalés J; Baumgärtner W
    Vet Immunol Immunopathol; 2019 Dec; 218():109939. PubMed ID: 31526954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.